Epidermolysis Bullosa Market Report 2026

The epidermolysis bullosa market size has grown strongly in recent years. It will grow from $3.43 billion in 2025 to $3.67 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to genetic disorder identification, limited treatment options, wound care product usage, rare disease advocacy growth, hospital-based supportive care.

The epidermolysis bullosa market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to gene therapy pipeline expansion, orphan drug incentives, personalized medicine adoption, homecare service growth, early genetic diagnosis. Major trends in the forecast period include rising focus on gene and cell therapies, increased demand for advanced wound care, growth in rare disease research programs, expansion of home-based supportive care, emphasis on multidisciplinary patient management.

The increasing research and development activities are expected to drive the growth of the epidermolysis bullosa market in the coming years. Research and development (R&D) involves systematic efforts to innovate, improve, or create new products, processes, or technologies. The expansion of R&D is fueled by growing demand for innovative treatments, advanced therapies, and precision medicine to address complex diseases. These activities facilitate the discovery of novel therapies, advanced wound care solutions, and potential gene- and cell-based treatments, improving diagnosis, management, and quality of life for patients with epidermolysis bullosa. For example, in April 2025, the Office for National Statistics, a UK-based executive office, reported that the UK government’s net expenditure on R&D increased to $21.6 billion (£17.4 billion) in 2023, up from $20 billion (£16.1 billion) in 2022, reflecting an 8.2% rise. Therefore, the growth of research and development is driving the epidermolysis bullosa market.

Key companies in the epidermolysis bullosa market are focusing on innovative treatments, such as redosable gene therapy, to improve long-term efficacy and patient outcomes. Redosable gene therapy refers to a treatment that can be administered multiple times to sustain or enhance therapeutic effects, unlike traditional one-time gene therapies. For instance, in May 2023, Krystal Biotech Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved VYJUVEK, a redosable gene therapy for patients aged six months and older with dystrophic epidermolysis bullosa (DEB). This therapy delivers a functional copy of the COL7A1 gene, addressing the underlying genetic defect causing DEB. Designed for topical application, VYJUVEK provides a convenient, less invasive alternative to traditional systemic treatments, improving patient care and accessibility.

In August 2023, Paradigm Therapeutics Inc., a US-based biopharmaceutical company, acquired the global rights to SD-101 from Amicus Therapeutics for an undisclosed amount. Through this acquisition, Paradigm Therapeutics aims to advance the development of a breakthrough therapy for all subtypes of epidermolysis bullosa (EB), accelerating its potential to provide a transformative solution for patients. Amicus Therapeutics, a US-based company, develops EB treatments focused on gene therapies, wound care, and innovative drugs.

Major companies operating in the epidermolysis bullosa market are LEO Pharma A/S, BridgeBio Pharma Inc., Amicus Therapeutics Inc., Amryt Pharma plc, Krystal Biotech Inc., Castle Creek Biosciences Inc., RHEACELL GmbH & Co. KG, BioMendics LLC, ProQR Therapeutics N.V., Holostem Terapie Avanzate Srl, TWi Biotechnology Inc., Abeona Therapeutics Inc., Phoenix Tissue Repair Inc., Phoenicis Therapeutics, Anterogen Co Ltd, Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, InMed Pharmaceuticals Inc., Aegle Therapeutics Corp., Wings Therapeutics Inc., RegeneRx Biopharmaceuticals Inc., Ishin Pharma, Menlo Therapeutics Inc., JCR Pharmaceuticals, Fibrocell Science Inc., Smith & Nephew plc, ConvaTec Group plc.

North America was the largest region in the epidermolysis bullosa market in 2025. The regions covered in the epidermolysis bullosa market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epidermolysis bullosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the epidermolysis bullosa market by increasing costs of imported wound dressings, gene therapy inputs, and specialty medications. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported advanced therapies. These tariffs raise treatment costs by increasing expenses for chronic wound care and emerging genetic therapies. However, they encourage domestic development of rare disease therapeutics, supporting long-term innovation and supply resilience.

The epidermolysis bullosa market research report is one of a series of new reports that provides epidermolysis bullosa market statistics, including epidermolysis bullosa industry global market size, regional shares, competitors with a epidermolysis bullosa market share, detailed epidermolysis bullosa market segments, market trends and opportunities, and any further data you may need to thrive in the epidermolysis bullosa industry. This epidermolysis bullosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epidermolysis bullosa (EB) is a group of rare genetic disorders characterized by extremely fragile skin, which results in blistering and wounds from minor friction or trauma. These disorders are studied to better understand genetic skin conditions, advance wound care therapies, and develop innovative gene and cell-based treatments to improve patient outcomes.

The primary product types for managing epidermolysis bullosa include antibiotics, analgesics, and others. Antibiotics are medications used to treat bacterial infections by either killing bacteria or preventing their growth. They can be administered through various routes, including injectable and oral forms, and are utilized by multiple end users such as hospitals, homecare settings, specialty clinics, and others.

The epidermolysis bullosa market consists of sales of wound care dressings, topical creams, gene therapy products, skin grafts, and pain management medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.